Cargando…

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine

While an important part of the world’s population is vaccinated against SARS-CoV-2, new variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent vaccine, most vaccinated individuals have antibodies that poorly neutralize several Omicron subvariants, including BQ.1.1,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tauzin, Alexandra, Beaudoin-Bussières, Guillaume, Benlarbi, Mehdi, Nayrac, Manon, Bo, Yuxia, Gendron-Lepage, Gabrielle, Medjahed, Halima, Perreault, Josée, Gokool, Laurie, Arlotto, Pascale, Morrisseau, Chantal, Tremblay, Cécile, Kaufmann, Daniel E., Martel-Laferrière, Valérie, Levade, Inès, Côté, Marceline, Bazin, Renée, Finzi, Andrés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535273/ https://www.ncbi.nlm.nih.gov/pubmed/37766332 http://dx.doi.org/10.3390/v15091926

Ejemplares similares

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
por: Tauzin, Alexandra, et al.
Publicado: (2023)

A Recent SARS-CoV-2 Infection Enhances Antibody-Dependent Cellular Cytotoxicity against Several Omicron Subvariants following a Fourth mRNA Vaccine Dose
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2023)

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine
por: Tauzin, Alexandra, et al.
Publicado: (2023)

SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Chatterjee, Debashree, et al.
Publicado: (2022)

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset
por: Anand, Sai Priya, et al.
Publicado: (2021)

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
por: Nayrac, Manon, et al.
Publicado: (2021)

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2020)

An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
por: Nicolas, Alexandre, et al.
Publicado: (2022)

Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
por: Nayrac, Manon, et al.
Publicado: (2022)

A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
por: Tauzin, Alexandra, et al.
Publicado: (2022)

Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection
por: Tauzin, Alexandra, et al.
Publicado: (2022)

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses
por: Tauzin, Alexandra, et al.
Publicado: (2021)

Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2
por: Gong, Shang Yu, et al.
Publicado: (2022)

Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization
por: Ding, Shilei, et al.
Publicado: (2020)

Temsavir Modulates HIV-1 Envelope Conformation by Decreasing Its Proteolytic Cleavage
por: Boutin, Marianne, et al.
Publicado: (2023)

SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2022)

Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV
por: Marchitto, Lorie, et al.
Publicado: (2023)

Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
por: Gong, Shang Yu, et al.
Publicado: (2021)

Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes
por: Chatterjee, Debashree, et al.
Publicado: (2022)

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4(+) T cell profile
por: Sannier, Gérémy, et al.
Publicado: (2023)

Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients
por: Tauzin, Alexandra, et al.
Publicado: (2022)

SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study
por: Lewin, Antoine, et al.
Publicado: (2021)

Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
por: Perreault, Josée, et al.
Publicado: (2020)

Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike
por: Prévost, Jérémie, et al.
Publicado: (2020)

Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity
por: Marchitto, Lorie, et al.
Publicado: (2023)

Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2020)

SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells
por: Ding, Shilei, et al.
Publicado: (2021)

Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity
por: Laumaea, Annemarie, et al.
Publicado: (2023)

Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay
por: Papenburg, Jesse, et al.
Publicado: (2021)

Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells
por: Richard, Jonathan, et al.
Publicado: (2021)

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies
por: Boutin, Marianne, et al.
Publicado: (2022)

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
por: Gasser, Romain, et al.
Publicado: (2021)

The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice
por: Ullah, Irfan, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study
por: Lewin, Antoine, et al.
Publicado: (2022)

Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron
por: Benlarbi, Mehdi, et al.
Publicado: (2022)

Piperidine CD4-mimetic compounds expose vulnerable Env epitopes sensitizing HIV-1-infected cells to ADCC
por: Ding, Shilei, et al.
Publicado: (2023)

Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality
por: Brunet-Ratnasingham, Elsa, et al.
Publicado: (2021)

A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells
por: Beaudoin-Bussières, Guillaume, et al.
Publicado: (2021)

Piperidine CD4-Mimetic Compounds Expose Vulnerable Env Epitopes Sensitizing HIV-1-Infected Cells to ADCC
por: Ding, Shilei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6rlj3a8ashhnki35k4duoklrne